Hypoglycemia-induced
brain injury is a potential complication of
insulin therapy in diabetic patients. Severe
hypoglycemia triggers a cascade of events in vulnerable neurons that may lead to neuronal death and
cognitive impairment even after
glucose normalization. Oxidative stress and the activation of
poly (ADP-ribose) polymerase-1 (PARP-1) are key events in this cascade. The production of
reactive oxygen species (ROS) induces DNA damage and the consequent PARP-1 activation, which depletes NAD+ and
ATP, resulting in
brain injury. One of the key precursors of NAD+ is
nicotinamide mononucleotide (NMN), which is converted to NAD+ and reduces production of ROS. Here we investigated whether NMN could reduce
brain injury after severe
hypoglycemia. We used a rat model of
insulin-induced severe
hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe
hypoglycemia, at the time of
glucose administration. One week after severe
hypoglycemia, hippocampal long-term potentiation (LTP), an electrophysiogic assay of synaptic plasticity, was examined and neuronal damage was assessed by
Hematoxylin-
Eosin staining. ROS accumulation, PARP-1 activation, NAD+ and
ATP levels in hippocampus were also measured. Cognitive function was assessed using the Morris water maze 6 weeks after severe
hypoglycemia. The addition of NMN reduced neuron death by 83 ± 3% (P < 0.05) after severe
hypoglycemia. The hippocampal LTP was significantly reduced by severe
hypoglycemia but showed recovery in the NMN addition group. NMN treatment also attenuated the severe
hypoglycemia-induced spatial learning and memory impairment. Mechanically, we showed that NMN administration decreased ROS accumulation, suppressed PARP-1 activation, and restored levels of NAD+ and
ATP in hippocampus. All these protective effects were reversed by
3-acetylpyridine (3-AP), which generates inactive NAD+. In summary, NMN administration following severe
hypoglycemia could ameliorate neuronal damage and
cognitive impairment caused by severe
hypoglycemia. These results suggest that NMN may be a promising therapeutic drug to prevent
hypoglycemia-induced
brain injury.